BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15604885)

  • 41. FLT3 mutations in childhood acute lymphoblastic leukemia.
    Armstrong SA; Mabon ME; Silverman LB; Li A; Gribben JG; Fox EA; Sallan SE; Korsmeyer SJ
    Blood; 2004 May; 103(9):3544-6. PubMed ID: 14670924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of FLT3 in leukemia.
    Gilliland DG; Griffin JD
    Curr Opin Hematol; 2002 Jul; 9(4):274-81. PubMed ID: 12042700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FLT3: ITDoes matter in leukemia.
    Levis M; Small D
    Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
    Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
    Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
    Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
    Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
    Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
    Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.
    Gilliland DG
    Best Pract Res Clin Haematol; 2003 Sep; 16(3):409-17. PubMed ID: 12935959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
    Knapper S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
    Paietta E; Ferrando AA; Neuberg D; Bennett JM; Racevskis J; Lazarus H; Dewald G; Rowe JM; Wiernik PH; Tallman MS; Look AT
    Blood; 2004 Jul; 104(2):558-60. PubMed ID: 15044257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
    Kiyoi H; Naoe T
    Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
    Xu F; Taki T; Yang HW; Hanada R; Hongo T; Ohnishi H; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
    Br J Haematol; 1999 Apr; 105(1):155-62. PubMed ID: 10233379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
    Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG
    Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ; Xue J; Corey SJ
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
    Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
    Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q; Nishiuchi R; Kitamura T; Kersey JH
    Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.